MSH6

Across TCGA pan-cancer cohorts, MSH6 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MSH6 data layer compared with 28 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MSH6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MSH6 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

PDAC, CCRCC, and HNSC are the cancer types where MSH6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.274	0.488	<.001	47	view →
CCRCC	OS	Median	II,III,IV	0.654	0.979	<.001	44	view →
HNSC	OS	Quartile	All	0.592	0.868	.010	7	view →
LSCC	OS	Tertile	II,III,IV	0.945	0.613	.019	6	view →
LUAD	OS	Tertile	All	0.621	0.920	.022	3	view →
UCEC	OS	Median	All	0.909	0.990	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MSH6–PDAC (DFS)

Open the PDAC breakdown →